This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. Roche

YTD September 2019 sales

Basel, 16 October 2019 Group

Severin Schwan Chief Executive Officer YTD 2019 performance

Outlook

5 YTD Sep 2019: Strong sales growth driven by Pharma Division

2019 2018 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 36.6 32.7 12 12

Diagnostics Division 9.5 9.4 1 4

Roche Group 46.1 42.1 9 10

CER=Constant Exchange Rates 6 Q3 2019: Group sales growth for the eighth consecutive year

14% 13%

12%

10% 9% 9% 8% 8% 7% 7% 7%7% 6% 8% 6% 6% 6% 6% 6% 6% 6% 6% 6% 5%

4% 5% 5% 4% 5% 4% 4% 4% 4% 4% 2% 3% 3% 2% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 15 16 16 16 16 17 17 17 17 18 18 18 18 19 19 19

All growth rates at Constant Exchange Rates (CER) 7 YTD Sep 2019: Strong sales growth in US, International and Japan

CHFbn 24 +12% 22 0% 20 18 16 14 12 +16% Diagnostics 10 0% +8% +14% Pharma 8 +1% 6 +10% 4 +3% -1% +20% 2 +11% 0 Japan Europe International US

All growth rates at Constant Exchange Rates (CER) 8 New products with strong momentum

CHFm % of Pharma sales CHFm 12,000 +935 29% 11,000 +3'942 +129 10,000 -1'020 9,000 8,000 21% 7,000 6,000 5,000 15% 46'066 4,000 11% 42'080 3,000 2,000 1,000 0 YTD Sep 2016 YTD Sep 2017 YTD Sep 2018 YTD Sep 2019 YTD Sep Pharma Pharma Pharma Diagnostics YTD Sep 2018 new other biosimilars Division 2019 products1 products exposed2 Erivedge Perjeta Kadcyla Gazyva Esbriet Cotellic Alecensa Tecentriq Ocrevus Hemlibra Xofluza Polivy Rozlytrek

All absolute values are presented in CHFm reported; 1 Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluza, Polivy, and Rozlytrek; 2 MabThera and 9 Herceptin in Europe and Japan Roche significantly advancing patient care BTDs and BDDs reflecting the quality of our research

10 Replace and extend the business: Keep up the momentum

Replace/extend existing businesses Entering new Achievements Q3 2019 franchises Gazyva, Entering new franchises Venclexta, MS: Polivy, Ocrevus: Treat early and with full dose to max benefit, MabThera/Rituxan Ocrevus good safety sustained (ECTRIMS) mosunetuzumab, risdiplam: Positive update on longer follow up for FIRE- CD20 x CD3, and SUNFISH (Type 1,2,3 data at WMS) idasanutlin satralizumab: Filing on track; Ph III mono data (ECTRIMS) Perjeta, Herceptin Kadcyla, Replace/extend existing businesses Herceptin + Perjeta FDC-SC Hemophilia A: Hemlibra Tecentriq: EU approval 1L NSCLC, 1L SCLC & 1L TNBC Tecentriq, JP approval 1L SCLC & 1L TNBC Alecensa, Avastin Ph III positive data in monotherapy NSCLC Rozlytrek, (IMPower110), positive Ph III data in bladder ipatasertib (IMvigor130) and early data in liver cancer CNS: H+P FDC-SC: Ph III positive data (FeDeriCa) faricimab Lucentis NMOSD, SMA, Rozlytrek: US approval in ROS1+ NSCLC & NTRK+ Port delivery system (PDS) Huntington’s, Autism, solid tumors Alzheimer’s Xofluza: Ph III positive data in children (miniSTONE2) Tamiflu Xofluza

FDC-SC=fixed dose combination subcutaneous; NMOSD=neuromyelitis optica spectrum disorder; SMA=spinal muscular atrophy; NSCLC=non-small cell lung cancer; SCLC=small cell lung 11 cancer; TNBC=triple-negative breast cancer; H+P=Herceptin + Perjeta YTD 2019 performance

Outlook

12 Diversifying the late stage pipeline & setting new Standards of Care

Product Status Product Status

risdiplam in SMA Phase II/III types 1/2/3 Tecentriq in 1L HCC Phase III

HTT-ASO in Huntington’s Phase II/III Tecentriq in neoadj TNBC Phase III

satralizumab in NMOSD Phase III (broad label); filing on track Tecentriq in 1L mUC Phase III Tecentriq in adj bladder cancer Phase III

Gazyva in lupus nephritis initiating Ph III Tecentriq in 1L melanoma Phase III (Dx+)

etrolizumab in UC and Crohn’s Phase III (induction and maintenance) Tecentriq in FL ovarian cancer Phase III

idasanutlin in R/R AML Phase III PDS in nAMD Phase III Herceptin + Perjeta FDC-SC Phase III faricimab in DME/nAMD Phase III ipatasertib 1/2L TNBC Phase III (Dx+)

ipatasertib 1L+ HR+ BC Phase III (Dx+)

Neuroscience Ophthalmology ipatasertib in 1L mCRPC Phase III (all comers and Dx+) Immunology Oncology Polivy in 1L DLBCL Phase III

Tecentriq in (neo)adj NSCLC Phase III

SMA=spinal muscular atrophy; NMOSD=neuromyelitis optica spectrum disorder; UC=ulcerative colitis; PDS=port delivery system; nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema; HCC=hepatocellular carcinoma; TNBC=triple-negative breast cancer; mUC=metastatic urothelial carcinoma; FL=front line; R/R AML=relapsed/refractory acute myeloid ; FDC=fixed dose combination; HR=hormone receptor; mCRPC=metastatic castration 13 resistant prostate cancer; DLBCL=diffuse large B-cell ; NSCLC=non-small cell lung cancer 2019 outlook further raised Sales growth to “high-single digit” from “mid- to high single digit”

Group sales growth1 • High-single digit (from mid- to high single digit)

Core EPS growth1 • Broadly in line with sales

Dividend outlook • Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER) 14 Pharmaceuticals Division

Bill Anderson CEO Roche Pharmaceuticals Roche significantly advancing patient care 28 BTDs reflecting the quality of our research

BTD=Breakthrough Therapy Designation 16 YTD Sep 2019: Pharmaceuticals Division sales Strong growth in US, International and Japan

2019 2018 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 36,559 32,702 12 12 United States 20,036 17,192 17 14 Europe 6,310 6,607 -4 -1 Japan 3,076 2,700 14 11 International 7,137 6,203 15 20

CER=Constant Exchange Rates 17 YTD Sep 2019: Portfolio rejuvenation on-going Strong growth from new products

Ocrevus +57% Hemlibra >500% Tecentriq +146% Perjeta +34% Avastin +8% Kadcyla +40% Alecensa +50% Actemra / RoActemra +9% Gazyva +40% Lucentis +9% Esbriet +9% TNKase / Activase +3% US Tamiflu -14% Europe MabThera -3% Japan Herceptin -9% International

CHFm -1,000 -800 -600 -400 -200 0 200 400 600 800 1,000

Absolute values and growth rates at Constant Exchange Rates (CER) 18 YTD Sep 2019: Oncology sales +8% driven by recent approvals

Oncology Q3 update HER2 franchise • Kadcyla: Strong global uptake in adj BC Avastin franchise • Strong uptake in China; first US biosimilar launched Hematology franchise • Venclexta:* Strong growth in 1L AML with US NPS >50% • Gazyva: Growth in 1L FL • Polivy: Strong US launch in R/R DLBCL Tecentriq • Growth driven by first-in-class launches in 1L SCLC & 1L TNBC Alecensa • Market leader in 1L ALK+ NSCLC with NPS around 70% Rozlytrek • Strong US launch in ROS1+ NSCLC and NTRK+ tumors

CER=Constant Exchange Rates; YTD Sep 2019 Oncology sales: CHF 21.1bn; CER growth +8%; * Venclexta sales booked by AbbVie and therefore not included; BC=breast cancer; AML=acute myeloid leukemia; NPS=new 19 patient share; FL=follicular lymphoma; R/R DLBCL=relapsed/refractory diffuse large B cell lymphoma; SCLC=small cell lung cancer; TNBC=triple negative breast cancer; NSCLC=non-small cell lung cancer HER2 franchise: Growth due to Perjeta and Kadcyla

CHFm YoY CER growth 3,500 HER2 franchise Q3 update • Perjeta (+33%): Global growth driven by eBC (APHINITY) 3,000 +9% +7% +5% • Kadcyla US (+87%): Growth in adjuvant setting for patients 2,500 +8% with residual disease (KATHERINE); switching as planned

2,000 • Kadcyla EU (+20%): Spontaneous use in adjuvant and 2L • Herceptin: First biosimilar in the US launched 1,500 • Positive Ph III (FeDeriCa) results for H+P FDC-SC 1,000 Outlook 2019 500 • US/EU: Continued Perjeta and Kadcyla uptake in eBC 0 • SABCS: Ph III (APHINITY) 2nd OS interim analysis (6 years) Q3 16 Q3 17 Q3 18 Q3 19 and Ph III (FeDeriCa) results to be presented Herceptin Perjeta Kadcyla

CER=Constant Exchange Rates; eBC=early breast cancer; H+P=Herceptin+Perjeta; FDC=fixed dose combination; SC=subcutaneous 20 Hematology franchise: Increasing contribution from Gazyva, Venclexta and Polivy Hematology franchise Q3 update CHFm YoY CER growth CD20 franchise 2,000 • MabThera (onc) EU (-24%): Erosion rate slows further • Gazyva (+45%): Growth mainly driven by 1L FL 0% 0% 1,500 -6% +3% Venclexta* • US: Strong growth mainly driven by 1L unfit AML

1,000 • US: NCCN guideline update to preferred regimen for Venclexta + Gazyva in 1L CLL (CLL14)

Polivy 500 • US: Strong uptake in 3L+ DLBCL and as CAR-T bridging therapy

Outlook 2019 0 • US: First Rituxan biosimilar expected in November Q3 16 Q3 17 Q3 18 Q3 19 • CD20 x CD3: Monotherapy and combination data at ASH MabThera/Rituxan (Onc) Gazyva/Gazyvaro Polivy

CER=Constant Exchange Rates; FL=follicular lymphoma; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; ASH=American Society of 21 Hematology * Venclexta sales are booked by AbbVie. Tecentriq Q3 update Accelerated global growth driven by lung and breast franchises

Lung franchise (NSCLC, SCLC) • US: Growth driven by first-in-class 1L SCLC and by 1L NSCLC CHFm YoY CER growth • EU: NPS in 2L NSCLC at 25%; 1L NSCLC & SCLC launches 600 +154% • Japan: Strong launch in 1L NSCLC 500 +146% GU franchise (bladder cancer) 400 +135% • US/EU: Stable shares in approved indications 300 +89% +71% Breast franchise (TNBC) 200 +44% +29% • US/EU: Growth driven by first-in-class 1L PDL1+ TNBC 100 Outlook 2019 0 • 2 Ph III read-outs in 1L HCC and 1L BRAF+ melanoma Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19

US Europe International Japan

CER=Constant Exchange Rates; SCLC=small cell lung cancer; NSCLC=non-small cell lung cancer; NPS=new patient share; TNBC=triple negative breast cancer; HCC=hepatocellular carcinoma 22 Tecentriq late stage pipeline Short term newsflow on new indications and adjuvant

Product Indication Filing Market Opportunity Product Indication Filing Date Market Opportunity

1L mUC 2019 risdiplam SMA 2019 in type 1/2/3

1L HCC 2019/20 satralizumab NMOSD 2019 filing on track

1L BRAFm Melanoma 2020 Ph II & III ongoing; HTT-ASO Huntington’s filing latest 2022 Tecentriq FL Ovarian Cancer 2020

Neoadj. TNBC 2020 Gazyva Lupus Nephritis initiating Ph III UC/ Adj. MIBC 2020 etrolizumab filing in UC in 2020 Crohn’s Disease Neoadj NSCLC 2021 fully recruited; PDS nAMD 1L/2L TNBC 2020 filing in 2020 1L+ HR+ BC recruitment ahead of ipatasertib 2020 faricimab nAMD/DME (chemo treated only) plan; filing in 2021 1L mCRPC 2020 Small: up to CHF 0.5 bn idasanutlin R/R AML 2020 Neuroscience Ophthalmology medium= CHF 0.5 to CHF 1bn

H+P FDC-SC eBC, 1L HER2+ BC 2019/20 Immunology Oncology large > CHF1bn Polivy 1L DLBCL 2020/21

mUC=metastatic urothelial cancer; HCC=hepatocellular carcinoma; FL=front line; TNBC=triple-negative breast cancer; MIBC=muscle invasive bladder cancer; NSCLC=non-small cell lung cancer; HR=hormone receptor; eBC=early breast cancer; mCRPC=metastatic castration resistant prostate cancer; R/R AML=relapsed/refractory acute myeloid leukemia; DLBCL=diffuse large B-cell lymphoma; SMA=spinal muscular atrophy; NMOSD=neuromyelitis optica spectrum disorder; 23 UC=ulcerative colitis; nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema Tecentriq + Avastin in 1L HCC Potential new SOC in HCC

Ph Ib (NCT02715531) results:

Arm A (T+A single arm): Arm F (T+A vs T): Best objective response and reduction Progression Free Survival by IRF RECIST 1.1 in target lesion per IRF-assessed RECIST v1.1

• Arm A: Durable responses of T + A with ORR of 36% by IRF RECIST 1.1 and 76% of responses ongoing after median follow up of 12.4 mo • Arm F: Statistically significant PFS improvement with T + A vs T monotherapy; mPFS of 5.6 vs 3.4 mo (HR 0.55, p = 0.0108) by IRF RECIST 1.1 demonstrating single-agent contribution to overall treatment effect • Ph III (IMbrave150) results (Tecentriq+Avastin vs ) expected in Q4 2019

ARM A: Lee M.S. et al. APPLE 2019 (Data cutoff: 14 June 2019; median follow-up: 12.4 months); ARM F: Lee M.S. et al. ESMO 2019 (Data cutoff: 14 June 2019; Median duration of follow-up: 6.6 months); b Stratification factors included are geographic region and AFP level (<400 ng/m vs. ≥ 400 ng/mL) at baseline. HCC=hepatocellular carcinoma; SOC=standard of care; T=Tecentriq; A=Avastin; ORR=objective response rate; CR=complete response; PR=partial response; PD=progressive disease; 24 SD=stable disease; IRF=independent review facility Tecentriq monotherapy in 1L PDL1+ NSCLC Positive results lay foundation for combination development

Ph III (IMpower110) results: NSCLC portfolio covering all segments

Overall survival (TC3 or IC3)

• Tecentriq with statistically significant OS improvement in the TC3 or IC3 population vs platinum based chemo (HR, 0.59 [95% CI: 0.40, 0.89]; P = 0.0106) as well as meaningful improvement in PFS, ORR and DOR • Tecentriq represents a promising 1L treatment option in patients with PD-L1 NSCLC • Extended PDL1 biomarker analysis for IMpower110 to be presented at upcoming conference

NSCLCL=non-small cell lung cancer; NSq=non-squamous; Sq=squamous 25 Lung cancer franchise: Alecensa in ALK+ NSCLC Strong 1L momentum continues in all markets

Alecensa Q3 update CHFm YoY CER growth • US (+15%): 1L New patient share > 70% 300 • EU (+164%): 1L New patient share approaching 70% 250 +50% • Japan (+14%): Strong uptake in new patients share 200 +62% • Strong launch momentum in China 150 +100% • Positive Ph III (B-FAST) results establish FMI’s blood-based 100 NGS to inform clinical decision-making in ALK+ NSCLC +172% 50 Outlook 2019 0 Q3 16 Q3 17 Q3 18 Q3 19 • NRDL listing in China expected

US Europe International Japan

CER=Constant Exchange Rates; NSCLCL=non-small cell lung cancer; NGS=next generation sequencing 26 Immunology franchise Annualized sales approaching CHF 9bn

CHFm YoY CER growth Immunology Q3 update 2,400 Esbriet (+6%) +7% +5% 2,000 +8% • Growth in mild to moderate segments +10%

1,600 Actemra (+9%) • EU: Remains leader in overall and 1L monotherapy RA 1,200 • Growth driven by RA new patient starts and GCA launches 800 Xolair (+3%) 400 • Growth driven by CIU 0 Q3 16 Q3 17 Q3 18 Q3 19 • Positive Ph III (POLYP I/II) results in nasal polyps filed in the US

MabThera/Rituxan (RA) Actemra IV Gazyva (lupus nephritis) Actemra SC Xolair CellCept Pulmozyme • BTD received; data to be presented at ASN and ACR/ARP Esbriet Other

CER=Constant Exchange Rates; RA=rheumatoid arthritis; GCA=giant cell arteritis; CIU=chronic idiopathic urticaria; BTD=breakthrough therapy designation; ASN=American Society of 27 Nephrology; ACR/ARP=American College of Rheumatology/Association for Rheumatology Professionals Neuroscience franchise: Ocrevus in MS Market leadership in US achieved with 18% total market share1

Ocrevus Q3 update CHFm YoY CER growth • US driven by continued growth in earlier lines and strong 1,000 +48% demand from returning patients +59% +67% • 37% new and switching patient share 800 +83% +104% • Strong launches in EU and International 600 +195% • ECTRIMS: Long term data >6 years show earlier treatment reduces risk of disability progression and wheelchair use 400 • >130,000 patients treated; >500,000 infusions

200 Outlook 2019

0 • Moving into earlier lines displacing orals Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 • Ongoing launches in EU and International US Europe International

CER=Constant Exchange Rates; 1. Market leadership by branded product, Symphony Health Claims Data 2019 28 Neuroscience franchise: Risdiplam in type 1 SMA 16 month CHOP-INTEND data presented at WMS

Ph III FIREFISH CHOP-INTEND: Continuous improvement from baseline over time

• Type 1 SMA • 1-7 months old • Two SMN2 gene copies Part 1: Dose-finding period followed by open-label extension • Cohort A: Low dose (n = 4) • Cohort B: High dose (n = 17) • EP: Safety, tolerability, PK and PD

Part 2: Efficacy & safety at the selected dose (n=41) • Primary endpoint: Proportion of infants sitting without support for 5 seconds after 12 months on • 82% (14/17) of Cohort B (high dose) had a CHOP-INTEND score ≥40 after 16 mo of treatment treatment as assessed by Gross • No infant has required tracheostomy or reached permanent ventilation Motor Scale of the BSID-III • Risdiplam filing on track for 2019; Ph II/III (SUNFISH) results in type 2/3 expected in Q4 19

Baranello G. et al WMS 2019; Data cut-off: 2 July 2019; Each line represents an individual infant. Intent-to-treat infants from FIREFISH Part 1 (N=21). Cohort A: Low-dose cohort. Cohort B: Dose adjusted per protocol. The three surviving infants from Cohort A were subsequently dose adjusted at ages 24.4, 20.6, and 20.8 months, respectively for each infant. A score of 0 was given for missed items in the CHOP-INTEND assessment; SMA=spinal muscular atrophy; WMS=World Muscle Society 29 Neuroscience franchise: Satralizumab in NMOSD A rare and debilitating autoimmune CNS disease

IL-6 is a key driver in the pathogenesis of NMOSD Satralizumab efficacy/safety profile

Clinical manifestation Highly effective • Comparable efficacy to best in disease • Optic neuritis and/or longitudinally treatments extensive transverse myelitis Flexible and convenient • Blindness, severe motor disability, • Only treatment studied as monotherapy and sensory disturbances, neuropathic in combination with immunosuppressants pain • Convenient Q4w SC dosing Per 100,000 • Relapsing: Disability can accumulate • Broadest flexibility on patient profile with each subsequent attack (AQP4+/-, only treatment for adolescent) Blind within 5 years • Anti-AQP4 autoantibodies in 70 to • Unique mechanism of action 1/2 Require wheelchair 80% of patients Well tolerated safety profile • ~40% of patients with NMOSD are • Lower rate of infections incl. serious 9/1 Female/male first misdiagnosed as having MS infections than placebo group

NMOSD=Neuromyelitis optica spectrum disorder; AQP4=aquaporin 4; MOA=mechanism of action; Q4W=every 4 weeks; SC=subcutaneous 30 Neuroscience franchise: Satralizumab as monotherapy in NMOSD 74% relapse risk reduction in AQP4+ patients

Ph III results monotherapy (SAkuraStar):

Risk of protocol-defined relapse (ITT population) Risk of protocol-defined relapse (AQP4+ patients)

• Relapse risk was reduced by 55% in the ITT population with 76% and 72% of patients being relapse-free at week 48 and 96, respectively • Relapse risk was reduced by 74% in AQP4+ patients (not affected by prior therapy or most recent attack type) with 83% and 77% being relapse-free at week 48 and 96, respectively • Filing in US/EU on track

Bennett J.L. et al., ECTRIMS 2019; Analysis based on ITT population; p-value (based on log-rank test) and hazard ratio (using Cox proportional-hazards model) stratified by prior therapy for prevention of NMOSD attack (B-cell-depleting or immunosuppressants/other) and by most recent attack in the year prior to screening (first attack vs relapse); NMOSD=Neuromyelitis optica spectrum disorder; CI=confidence interval; HR=hazard ratio; ITT=intention to treat 31 Hemophilia A franchise Hemlibra with 18% total US patient share after 23 months

CHFm

400 Hemlibra Q3 update 350 • US: Strong uptake in non-inhibitors driven by large centers 300 and patient requests 250 • Japan: Strong uptake in non-inhibitors and inhibitors 200 • Overall >4,000 patients treated globally 150 100 Outlook 2019 50 • US/EU: Uptake in non-inhibitors and inhibitors 0 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19

US Europe International Japan

CER=Constant Exchange Rates 32 New products exceed annualized sales of CHF 15bn* First sales for Polivy and Rozlytrek achieved

CHFm % of Pharma Sales

4,500 4,000 31% 3,500 3,000 23% 2,500

2,000 16% 1,500 12% 1,000 500 0 Q3 16 Q3 17 Q3 18 Q3 19

Erivedge Perjeta Kadcyla Gazyva Esbriet Cotellic Alecensa Tecentriq Ocrevus Hemlibra Xofluza Polivy Rozlytrek

33 Upcoming conferences and IR events in 2019*

Hematology franchise: • mosunetuzumab: Ph I (GO29781) safety/efficacy update in R/R NHL • CD20 x CD3 + Tecentriq: Ph I results • CD20 x CD3 + Gazyva: Ph I results • Polivy + Gazyva + lenalidomide: Ph I (GO29834; inHarmony) in R/R FL Breast franchise: • Perjeta + Herceptin: Ph III (APHINITY) 2nd OS 5-year update in eBC • P+H FDC-SC: Ph III (FeDeriCa) in HER2+ eBC GI franchise: • Tecentriq + Avastin: Ph III (IMbrave150) in 1L HCC Lung franchise: • Tecentriq: Ph III (IMpower110) extended PDL1 biomarker analysis Immunology franchise: • Gazyva + SOC: Ph II (NOBILITY) in lupus nephritis • Xolair: Ph III (POLYP I/II) in nasal polyps at ACAAI

Roche Virtual pRED Event Roche Virtual ASN/ACR Event Roche Virtual ASH Event Monday, 11 Nov 2019 Tuesday, 12 Nov 2019 Tuesday, 10 Dec 2019 14:00 to 15:30 CET 16:30 to 17:30 CET tba

* Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change; tba=to be announced 34 2019: Key late-stage news flow*

2020 IA passed

**

Additional 2019 news flow: • Gazyva: Positive Ph II results in lupus nephritis • H+P FDC-SC: Positive Ph III (FeDeriCa) in HER2+ eBC • MabThera/Rituxan: EU approval of pemphigus vulgaris • Xolair: Positive Ph III results in nasal polyps • Rituxan: US approval in GPA and MPA for pediatrics • Herceptin Hylecta: US approval SC formulation • Tecentriq: Positive Ph III (IMpower110) in 1L NSCLC • Tecentriq+chemo: Positive Ph III (Imvigor130) in 1L mUC • Rozlytrek: Japan early approval for NTRK+ solid tumors • satralizumab: Positive Ph III (SAkuraStar) in NMOSD 35 *Outcome studies are event-driven: timelines may change; ** Study met its primary endpoint of PFS: 22.4m vs. 11.5m with a HR of 0.63; Higher proportion of deaths in Venclexta arm; IA=interim analysis Diagnostics Division

Thomas Schinecker CEO Roche Diagnostics YTD Sep 2019: Diagnostics Division sales Growth driven by Centralised and Point of Care Solutions and Molecular Diagnostics

2019 2018 Change in % CHFm CHFm CHF CER Diagnostics Division 9,507 9,378 1 4 Centralised and Point of Care Solutions 5,766 5,625 3 5 Molecular Diagnostics 1,547 1,468 5 7 Diabetes Care 1,395 1,484 -6 -2 Tissue Diagnostics 799 801 0 0

CER=Constant Exchange Rates; underlying growth of Molecular Diagnostics excluding sequencing business: +6% 37 YTD Sep 2019: Diagnostics Division regional sales Growth driven by Asia Pacific and EMEA

Japan North America +3% -1% EMEA1 ~4% of divisional sales ~25% of divisional sales +3% ~38% of divisional sales

Asia Pacific Latin America +9% +9% ~27% of divisional sales ~6% of divisional sales

+10% growth in E7 countries2

1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea and Turkey; all growth rates at Constant Exchange Rates (CER) 38 YTD Sep 2019: Diagnostics Division highlights Growth driven by Immunodiagnostics

YoY CER growth Centralised • Immunodiagnostics (+10%) and Point +5% of Care • Sales affected by decline in coagulation monitoring Solutions

Molecular • Blood screening (+9%); POC MDx (+26%); Virology 1 +7% Diagnostics (+1%)

Diabetes • Blood glucose monitoring (-3%); Insulin delivery -2% Care systems (-2%)

2 • Primary staining (+1%); Advanced staining (+2%); Tissue EMEA 0% Reagents (+5%) Diagnostics North America • BenchMark and Discovery Ultra shipment delays RoW

CHFbn 0.0 1.0 2.0 3.0 4.0 5.0 6.0

1 Underlying growth of Molecular Diagnostics excluding sequencing business: +6%; 2 EMEA=Europe, Middle East and Africa; CER=Constant Exchange Rates 39 FDA clearance for cobas pro® integrated solutions Key launch to further grow the medium/high volume segment

• Broadest Serum Work Area assay menu consolidated on a single platform • Up to 2,200 tests per hour with 3 modules working in parallel and synchronized to improve efficiency • Up to 3¼ hours less operating time 1 • Automated calibration in clinical chemistry significantly reducing operator hands on time • Reduces turnaround times in delivering results to cobas c 503 cobas e 801 physicians and patients

1 for a daily routine workload, as compared to cobas 6000 <501|501|601> 40 Largest installed base worldwide

Integrated Core Lab +10% cobas 6000/8000

+22% cobas 6800/8800

+9% Connectivity

+10% +10% Preanalytics Middleware cobas 4000 +7%

YTD 2019 Growth Growth rates being from the period of January 1, 2019 to August 31, 2019 41 Launch of cobas® EBV and cobas® BKV Transplant menu expansion on cobas® 6800/8800 Systems

• Perform critical transplant virus testing (CMV, EBV, BKV) from a single sample on cobas® 6800/8800 with full automation and proven performance • Enables healthcare professionals to determine transplant patients at risk of further complications caused by reactivation of these viruses • EBV and BKV tests received breakthrough device designation from the FDA • Market size (molecular transplant diagnostics): USD 605m (CAGR +8%)

EBV=Epstein-Barr Virus, BKV=BK Virus, CMV=Cytomegalovirus 42 FDA approval of Babesia test on cobas® 6800/8800 Roche’s first whole blood donor screening assay

• Undetected Babesia infection can be fatal in patients receiving blood transfusions from infected donors • Detection of 4 common species of Babesia parasites that live in red blood cells • Simplified Babesia sample preparation through new whole blood collection tube, enabling more efficient laboratory processing and future menu expansion

43 cobas® 6800/8800 systems driving growth in molecular Continued menu expansion of our high medical value assays

Antimicrobial Donor Screening Infectious Disease Sexual Health Transplant Respiratory Stewardship MPX HIV-1 HPV CMV MTB MTB-RIF/INH WNV HBV CT/NG EBV Launch 2019 MAI (CE-IVD in 2019, US-IVD in 2020) DPX HCV TV/MG MPLX Respiratory (CE-IVD, US-IVD in 2019) BKV Launch 2019 (CE-IVD in 2020, US-IVD in 2021) HEV HIV-1/2 Qual (CE-IVD in 2019, US-IVD in 2020) (Not available in the US) (CE-IVD, US-IVD in 2020) HPV Self Sampling (CE-IVD in 2020) CHIKV/DENV (Not available in the US) Zika (US-IVD, CE-IVD in 2019)

Babesia Launch 2019 (US-IND, US-IVD & CE-IVD in 2019)

Installed instrument base: 729*

*August 2019

MPX=multiplex detection of HIV-1, HIV-2, HCV and HBV; WNV=West Nile virus; DPX=duplex detection of parvovirus B19 and HAV; HEV=Hepatitis E virus; CHIKVV=chikungunya virus; DENV=Dengue virus; CMV=Cytomegalovirus; MTB=Mycobacterium tuberculosis; MAI=Mycobacterium avium-intracellulare infection; RIF=rifampicin; INH=isoniazid (detection of RIF/INH resistance in MTB positive samples); TV=trichomonas vaginalis; MG=mycoplasma genitalium; Babesia=detection of babesiosis caused 44 by tick-born parasites; EBV=Epstein-Barr virus post-transplant monitoring; BKV=BK virus post-transplant monitoring; ADV=Adenovirus post-transplant monitoring; HSV-1/2/VZV=multiplex detection of Herpes simplex virus 1 and 2 and Varicella-zoster virus; MPLX=detect and discriminate multiple (up to 14) pathogens associated with a clinical syndrome Expansion of Global Access Program beyond HIV Delivering detection to enable treatment of hepatitis, tuberculosis and cervical cancer in lower access regions

• Focus on the UN Sustainable Development Goals (SDGs) which aim to “end the global tuberculosis (TB) epidemic” 95:90:001 • Contribute to Hepatitis Elimination Goals 90:65:802 • Focus on global call for action to prevent cervical cancer 90:70:90 goals3

1 Targets to reduces TB deaths by 95%, cut new cases by 90% btw 2015 and 2035, and ensure that no family is burdened with catastrophic expenses due to TB; 2 Targets to reduce new hepatitis infections by 90%, deaths by 65%, and treat 80% of HBV and HCV patients by 2030; 3 Targets to have 90% of girls vaccinated with HPV vaccine by 15 years of age, 70% of women HPV screened at 35 and 45 years of age, and 90% of women identified with cervical disease receive treatment. 45 Key launches 2019

Area Product Description Market1 Instruments/ Workflow cobas prime Pre-analytical platform to support cobas 6800/8800 CE/US Devices

Coagulation Protein C Chrom Quantitative determination of protein C in citrated plasma on cobas t 511 / t 711 analyzers CE Tests/ cobas TV/MG High volume solution for TV/MG testing; dual-target test with ability to test with CT/NG from the same US Assays Microbiology specimen during the same run cobas vivoDx MRSA Live cell assay for prevention and control of MRSA infections CE Tissue Dx VENTANA HER2 Dual ISH Fully automated, brightfield ISH assay to determine eligibility for HER2 CE Central cobas Infinity Central Lab 3.0 One global laboratory middleware solution realizing a very high degree of integration in the WW Laboratory laboratory Algorithm - Breast Panel Whole slide analysis image analysis algorithm (HER2, ER, PR, Ki-67) CE Tissue Dx Algorithm - PD-L1 Lung Whole slide analysis image analysis algorithm (SP263) CE NAVIFY Mutation Profiler Software as a medical device for annotating, variant classification, clinical interpretation and reporting CE US2 Sequencing from comprehensive genomic profile testing Software Informing on treatment options based on local drug labels, medical guidelines and clinical trial 2 NAVIFY Therapy Matcher outcomes CE US NAVIFY Tumor Board V2 Integrating a GEHC DICOM imaging viewer into the Tumor Board to support the radiologist Decision WW NAVIFY Oncology Workflow Integration of patient’s longitudinal history, diagnosis, and treatment planning by leveraging relevant Support WW V1 guidelines Diabetes Accu-Chek Sugar View 2.0 For non-insulin dependent T2 PwDs, allowing for meter-free blood glucose monitoring using Accu- CE Care (non-ISO) Chek Active test strips and a smartphone camera

1 CE: European Conformity, US: FDA approval, WW: Worldwide; GEHC DICOM: GE Healthcare Digital Imaging and Communications in Medicine; T2: Type II Diabetes; PwDs: People with Diabetes 46 2 NAVIFY Mutation Profiler and Therapy Matcher received CE mark; US approval expected by end of 2019. Finance

Alan Hippe Chief Financial Officer YTD Sept 2019: Highlights

Sales • Strong underlying Group sales growth (+10%) • +12% growth for Pharma Division with US (+14%), International (+20%) and Japan (+11%); Europe back to growth again (+5% in Q3 2019) • +4% growth for Diagnostics Division

Currency impact • Negative impact driven by EUR and LATAM currencies, partially offset by USD

Bond repayments and issuances in Q3 2019

• Scheduled bond repayments of USD 2bn: – USD 500m, 5 years, floating – USD 1,500m, 5 years, 2.25% notes

All growth rates at Constant Exchange Rates (CER) 48 Group sales YTD Sep 2019 CER sales increase of +10% driven by US and International

+14% -1% +20% +11% +10% +9%

Pharma Division Dia Division +12% +4%

+342 +291 -219

+1,238

-63 +4,205 +3,986 PY: -515 +2,397

1 United States Europe Intl. Chugai Dia Division Group Fx Group (Japan) CHF

Absolute values in CHFm at Constant Exchange Rates (avg full year 2018); 1 avg full year 2018 to avg September 2019 fx 49 Exchange rate impact on sales growth Negative impact driven by EUR and LATAM currencies, partially offset by USD

+1.2p +0.2p 0.0p -0.3p -0.4p -0.6p -0.6p

CER CHF sales sales growth +10.0% +9.5% growth YTD Sep 2019 YTD Sep 2019 vs. vs. YTD Sep 2018 YTD Sep 2018

CER USD JPY Other Other As-Pac LATAM EUR CHF Europe CER = Constant Exchange Rates (avg full year 2018) 50 Low currency impact expected in 2019

CHF / USD

Average +5% +3% +2% +2% YTD 2018 Assuming the 30 September 2019 exchange rates 1.00 1.00 1.00 0.99 remain stable until end of 2019, 0.97 1 0.98 2019 impact is expected to be (%p): 0.95 0.97 Assumed average YTD 2019 Q1 HY Sep FY 0.99 1.00 1.00 1.01 1.01 0.99 0.99 0.98 0.99 0.99 0.99 0.99 YTD Monthly avg fx rates 2019 FX rates at 30 September 2019 Sales 1 0 -1 -1 CHF / EUR Core operating -3% -3% -4% -4% 0 -1 profit 1.17 1.16 1.16 1.15 1.13 1.12 1.11 Core EPS 0 -1 1.13

1.13 1.14 1.13 1.13 1.13 1.12 1.11 1.09 1.09 1.08 1.08 1.08

1 On group growth rates 51 2019 outlook further raised Sales growth to “high-single digit” from “mid- to high single digit”

Group sales growth1 • High-single digit (from mid- to high single digit)

Core EPS growth1 • Broadly in line with sales

Dividend outlook • Further increase dividend in Swiss francs

1 At Constant Exchange Rates (CER) 52 Changes to the development pipeline Q3 2019 update

New to phase I New to phase II New to phase III New to registration

2 NMEs: 1 AI: 1 NME: RG6076 CD19-4-1BBL - heme tumors RG3648 Xolair - food allergy RG6168 satralizumab - NMOSD RG6102 brain shuttle gantenerumab - Alzheimer’s

Removed from phase I Removed from phase II Removed from phase III Removed from registration

4 NMEs: 1 NME: 2 AIs: 2 AIs following approval in all key RG6109 - AML RG7625 petesicatib - autoimmune disease RG7601 Venclexta + bortezomib - MM territories: RG6123 - solid tumors RG7446 Tecentriq + nab-paclitaxel - 1L RG7446 Tecentriq + nab-paclitaxel - 1L RG6146 BET inh - solid and heme tumors squamous NSCLC TNBC RG6148 - HER2+ breast cancer RG7446 Tecentriq + chemo - 1L extensive 1 AI: stage SCLC RG7446 Tecentriq + Tarceva/Alecensa - NSCLC

53 Status as of October 16, 2019 Roche Group development pipeline

Phase I (38 NMEs + 19 AIs) Phase II (14 NMEs + 10 AIs)

RG6026 CD20 x CD3 / combos heme tumors RG7769 PD1-TIM3 biMAb solid tumors RG6180 iNeST* + malignant melanoma RG6076 CD19-4-1BBL heme tumors RG7802 cibisatamab ± T solid tumors RG6058 tiragolumab ± T NSCLC RG6107 crovalimab PNH RG7827 FAP-4-1BBL FP solid tumors idasanutlin polycythemia vera RG7388 RG6114 mPI3K alpha inh HR+ BC RG7828 mosunetuzumab / combos heme tumors idasanutlin AML fit 1L RG6160 - multiple myeloma RG7876 selicrelumab combos solid tumors RG7421 Cotellic + Tecentriq ± taxane TNBC RG6171 SERD (3) ER+ (HER2-) mBC CHU Raf/MEK dual inh solid tumors RG7440 ipatasertib TNBC neoadj RG6180 iNeST*± T solid tumors CHU glypican-3 x CD3 solid tumors RG7446 Tecentriq SC NSCLC RG6185 pan-RAF inh + Cotellic solid tumors CHU codrituzumab HCC RG7596 Polivy () r/r FL RG6194 HER2 x CD3 BC RG6151 - asthma Venclexta + Rituxan DLBCL RG7159 anti-CD20 combos heme tumors RG6173 - asthma RG7601 Venclexta + azacitidine 1L MDS Cotellic + Zelboraf + T melanoma RG6244 - asthma Venclexta + fulvestrant 2L HR+BC RG7421 Cotellic + T 2L BRAF WT mM RG7835 - autoimmune diseases RG6149 ST2 MAb asthma Cotellic + T RCC, bladder, head & neck ca RG7880 IL-22Fc inflammatory diseases RG7159 Gazyva lupus ipatasertib + Taxane + T TNBC RG6004 HBV LNA HBV RG7845 fenebrutinib RA, lupus, CSU RG7440 ipatasertib + rucaparib mCRPC, solid tumors RG6084 - HBV CHU nemolizumab# pruritus in dialysis patients Tecentriq (T) solid tumors RG6217 - HBV NOV TLR4 MAb autoimmune diseases T-based Morpheus platform solid tumors RG7854 TLR7 agonist (3) HBV RG1662 basmisanil CIAS T + Avastin + Cotellic 2/3L CRC RG7861 anti-S. aureus TAC infectious diseases RG6100 Tau MAb Alzheimer’s RG7446 T ± Avastin ± chemo HCC, GC, PaC RG7907 HBV CpAM (2) (Capsid) HBV RG7412 crenezumab familial Alzheimer’s healthy pts T + anti-CD20 combos heme tumors RG7992 FGFR1/KLB MAb metabolic diseases RG7916 risdiplam§ SMA T + K/HP HER2+ BC RG6000 - ALS RG7906 - psychiatric disorders T + rucaparib ovarian ca RG6102 brain shuttle gantenerumab Alzheimer’s RG7935 prasinezumab Parkinson's RG7461 FAP IL2v FP combos solid tumors RG6237 - neuromuscular disorders RG6147 - geographic atrophy Venclexta + idasanutlin AML RG7816 GABA Aa5 PAM autism IONIS ASO factor B geographic atrophy Venclexta + AMG176 AML RG6179 - DME RG7601 Venclexta ± azacitidine r/r MDS RG7774 - retinal disease NMEs CardioMetabolism Venclexta + r/r AML RG7921 - wAMD Additional Indication (AI) Neuroscience Venclexta + Cotellic + T MM CHU PTH1 recep. ago hypoparathyroidism Oncology / Hematology Ophthalmology CHU - hyperphosphatemia Immunology Other Infectious Diseases CHU - endometriosis

RG-No - Roche/Genentech NOV- Novimmune managed §Ph2 pivotal # out-licensed to Galderma and Maruho AD 54 Status as of October 16, 2019 CHU- Chugai managed *Individualized NeoAntigen Specific Immunotherapy T=Tecentriq Roche Group development pipeline

Phase III (10 NMEs + 31 AIs) Registration (4 NMEs + 5 AIs)

RG7446/RG7853/R RG3502 Kadcyla1 HER2+ eBC RG3502 Kadcyla + Perjeta HER2+ eBC Tecentriq or Alecensa or 1LNSCLC Dx+ RG6264 Perjeta + Herceptin FDC SC HER2+ BC G6268 Rozlytrek (entrectinib)1 ROS1+ NSCLC RG6268 Venclexta r/r MM t(11:14) 1 RG7388 idasanutlin + chemo AML RG7601 Rozlytrek (entrectinib) NTRK+ tumor-agnostic ipatasertib + abiraterone 1L CRPC Venclexta + HMA 1L AML RG7446 T + nab-paclitaxel 2 1L non-sq NSCLC RG7440 ipatasertib + chemo 1L TNBC/HR+ BC RG7853 Alecensa ALK+ NSCLC adj RG7596 Polivy (polatuzumab vedotin)1 r/r DLBCL Xolair nasal polyps 1 RG7421 Cotellic + Zelboraf + T 1L BRAFm melanoma RG3648 RG7601 Venclexta + Gazyva 1L CLL RG7596 Polivy (polatuzumab vedotin) 1L DLBCL Xolair food allergy Xofluza 1 influenza RG6152 etrolizumab ulcerative colitis 3 Tecentriq NSCLC adj RG7413 Xofluza influenza, high risk Tecentriq MIBC adj etrolizumab Crohn’s RG6168 satralizumab NMOSD Tecentriq NMIBC, high risk Xofluza influenza, hospitalized pts Tecentriq Dx+ 1L sq + non-sq NSCLC RG6152 Xofluza influenza, pediatric Tecentriq RCC adj Xofluza influenza post exposure prophylaxis T + chemo + Avastin 1L ovarian cancer RG1450 gantenerumab Alzheimer’s RG6042 HTT ASO Huntington’s T + pemetrexed 1L non-sq NSCLC 1 Approved in US T ± chemo SCCHN adj RG6206 anti-myostatin adnectin DMD RG7446 2 Approved in EU Tecentriq HER2+ BC neoadj RG7314 balovaptan autism 3 Filed in US T + paclitaxel 1L TNBC RG6321 port delivery system with ranibizumab wAMD faricimab DME T + capecitabine or carbo/gem 1L TNBC RG7716 T + paclitaxel TNBC adj faricimab wAMD T + nab-paclitaxel TNBC neoadj T + Avastin 1L HCC New Molecular Entity (NME) CardioMetabolism Additional Indication (AI) Neuroscience T + Avastin 1L RCC Oncology / Hematology Ophthalmology T ± chemo 1L mUC Immunology Other Infectious Diseases

55 Status as of October 16, 2019 NME submissions and their additional indications Projects in phase II and III

Port Delivery System RG6321 with ranibizumab wAMD risdiplam etrolizumab RG7916 RG7413 SMA ulcerative colitis tiragolumab + satralizumab ✓ Xofluza HTT ASO RG6168 RG6152 RG6058 Tecentriq RG6042 NMOSD influenza, pediatric Huntington’s NSCLC anti-myostatin Xofluza (EU) iNeST* gantenerumab Xofluza RG6152 RG6206 adnectin RG6180 RG1450 RG6152 influenza oncology Alzheimer‘s influenza, hospitalized pts DMD Perjeta + Herceptin Xofluza (EU) idasanutlin basmisanil faricimab RG6152 RG6264 FDC SC RG7388 RG1662 RG7716 influenza, high risk AML fit 1L CIAS wAMD HER2+ BC Xofluza idasanutlin + chemo idasanutlin Tau MAb ST2 Mab RG6152 influenza post-exposure RG7388 RG7388 RG6100 RG6149 polycythemia vera Alzheimer’s asthma prophylaxis AML Rozlytrek (entrectinib) ipatasertib + faricimab ipatasertib balovaptan etrolizumab RG6268 (EU) ✓ RG7440 abiraterone RG7716 RG7440 RG7314 RG7413 DME TNBC neoadj autism Crohn’s ROS1+ NSCLC 1L CRPC Rozlytrek (entrectinib) Polivy (polatuzumab Polivy (polatuzumab Ipatasertib + chemo prasinezumab fenebrutinib RG6268 (EU) ✓ RG7440 RG7596 vedotin) RG7596 vedotin) RG7935 RG7845 1L TNBC / HR+ BC Parkinson’s autoimmune diseases NTRK+ tumor-agnostic 1L DLBCL r/r FL 2019 2020 2021 2022 and beyond

✓ Indicates submission to health authorities has occurred New Molecular Entity (NME) CardioMetabolism Unless stated otherwise submissions are planned to occur in US and EU Additional Indication (AI) Neuroscience Oncology / Hematology Ophthalmology Immunology Other Infectious Diseases FDC =fixed-dose combination *Individualized NeoAntigen Specific Immunotherapy 56 Status as of October 16, 2019 AI submissions for existing products - Projects in phase II and III

Kadcyla + Perjeta RG3502 HER2+ eBC Cotellic + Tecentriq + New Molecular Entity (NME) Immunology Neuroscience RG7421 Zelboraf Additional Indication (AI) Infectious Diseases Ophthalmology 1L BRAFmut melanoma Oncology / Hematology CardioMetabolism Other Tecentriq + nab-paclitaxel RG7446 TNBC neoadj

Tecentriq + pemetrexed RG7446 1L non-sq NSCLC

Tecentriq + Avastin Tecentriq SC RG7446 RG7446 1L RCC NSCLC

Tecentriq + paclitaxel Tecentriq Gazyva RG7446 RG7446 RG7159 1L TNBC NSCLC adj lupus nephritis Cotellic + Tecentriq ± Tecentriq Tecentriq RG7446 RG7421 taxane RG7446 HER2+ BC neoadj MIBC adj TNBC Tecentriq ± chemo Tecentriq + paclitaxel Venclexta RG7446 RG7446 RG7601 1L mUC TNBC adj r/r MM t(11:14) Tecentriq + chemo + Tecentriq Venclexta + Rituxan RG7446 Avastin RG7446 RG7601 High risk NMIBC DLBCL 1L ovarian cancer Xolair Tecentriq Xolair Tecentriq Venclexta + azacitidine RG3648 RG7446 RG3648 RG7446 RG7601 nasal polyps 1L non-sq + sq NSCLC Dx+ Food allergy RCC adj 1L MDS

Kadcyla✓ Tecentriq + Avastin Venclexta + HMA Tecentriq + chemo Venclexta + fulvestrant RG3502 RG7446 RG7601 RG7446 RG7601 HER2+ eBC 1L HCC 1L AML SCCHN adj 2L HR+BC Tecentriq or Rozlytrek Tecentriq + capecitabine or Venclexta + Gazyva ✓ Alecensa RG7446/ Alecensa RG7601 RG7853 (entrectinib) RG7446 carbo/gem RG7853 1L CLL 1L NSCLC Dx+ RG6268 ALK+ NSCLC adj 1L NSCLC Dx+ TNBC 2019 2020 2021 2022 and beyond 57 ✓ Indicates submission to health authorities has occurred Status as of October 16, 2019 Unless stated otherwise submissions are planned to occur in US and EU pipeline overview

Phase I (11 NMEs + 21 AIs) Phase III (19 AIs)

RG6026 CD20 x CD3 / combos heme tumors AMGN** Tecentriq + talimogene laherp TNBC, CRC RG7421 Cotellic + Zelboraf + T 1L BRAFm melanoma RG6076 CD19-4-1BBL heme tumors BLRX** Tecentriq + BL-8040 AML, solid tumors Tecentriq NSCLC adj RG6160 - multiple myeloma CRVS** Tecentriq + CPI-444 solid tumors Tecentriq MIBC adj RG6180 iNeST* ± T solid tumors EXEL** Tecentriq + solid tumors Tecentriq high risk NMIBC RG6194 HER2 x CD3 BC HALO** Tecentriq + PEGPH20 CCC, GBC Tecentriq NMIBC Cotellic + Zelboraf + T melanoma INO** Tecentriq + INO5401+INO9012 bladder ca Tecentriq Dx+ 1L sq + non-sq SCLC RG7421 Cotellic + T 2L BRAF WT mM KITE** Tecentriq + KTE-C19 r/r DLBCL Tecentriq RCC adj Cotellic + T RCC, bladder, head & neck ca T + chemo+ Avastin 1L ovarian cancer RG7440 ipatasertib + Taxane + T TNBC MORPHEUS Platform - Phase Ib/II (7 AIs) T + pemetrexed 1L non-sq NSCLC Tecentriq (T) solid tumors T-based Morpheus pancreatic cancer RG7446 T ± chemo SCCHN adj T-based Morpheus platform solid tumors T-based Morpheus gastric cancer Tecentriq HER2-pos. BC neoadj T + Avastin + Cotellic 2/3L CRC T-based Morpheus HR+ BC T + nab-paclitaxel 1L TNBC RG7446 T ± Avastin ± chem HCC, GC, PaC T-based Morpheus NSCLC T + capecitabine or carbo/gem 1L TNBC RG7446 T + Tarceva/Alecensa NSCLC T-based Morpheus 2L TNBC T + paclitaxel TNBC adj T + anti-CD20 combos heme tumors T-based Morpheus CRC T + nab-paclitaxel TNBC neoadj T + K/HP HER2+ BC T-based Morpheus mUC T + Avastin RCC T + rucaparib ovarian ca T + Avastin 1L HCC RG7461 FAP IL2v FP combos solid tumors Phase II (2 NMEs + 5 AIs) T ± chemo 1L mUC RG7446/RG7853/ RG7601 Venclexta + Cotellic + T MM RG6180 iNeST* + pembrolizumab malignant melanoma Tecentriq or Alecensa or entrectinib 1L NSCLC Dx+ RG6268 RG7769 PD1-TIM3 biMAb solid tumors RG6058 tiragolumab ± T NSCLC RG7802 cibisatamab ± T solid tumors RG7421 Cotellic + Tecentriq ± taxane TNBC RG7827 FAP-4-1BBL FP solid tumors RG7446 Tecentriq SC NSCLC Registration (1 AI) RG7828 mosunetuzumab / combos heme tumors Gradalis** Tecentriq + Vigil ovarian ca # RG7876 selicrelumab combos solid tumors GTHX** Tecentriq + trilaciclib SCLC RG7446 T + nab-paclitaxel 1L non-sq NSCLC CHU glypican-3 x CD3 solid tumors IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma # Approved in EU

** External collaborations: AMGN – Amgen oncolytic virus; BLRX - BioLine Rx New Molecular Entity (NME) RG-No Roche/Genentech CXCR4 antag; CRVS – Corvus ADORA2A antag; EXEL – Exelexis’ TKI; Gradalis – EATC therapy; GTHX – CDK4/6; HALO – Halozyme PEGPH20; Additional Indication (AI) *Individualized NeoAntigen Specific Immunotherapy IMDZ – Immune Design CMB305; INO - Inovio T cell activating immunotherapy Oncology T=Tecentriq (INO-5401), IL-12 activator (INO-9012); JNJ – Janssen CD38 MAb; KITE – Kite KTE-C19 58 Status as of October 16, 2019 Major pending approvals 2019

US EU China Japan-Chugai

Tecentriq + nab-paclitaxel Polivy (polatuzumab vedotin) CellCept Kadcyla RG7446 1L non sq NSCLC RG7596 r/r DLBCL RG99 lupus nephritis RG3502 HER2+ eBC adj Filed Nov 2018 Filed Dec 2018 Filed Aug 2018 Filed Aug 2019 Xofluza Rozlytrek (entrectinib) MabThera Rozlytrek (entrectinib) RG6152 Influenza, high risk pts RG6268 ROS1+ NSCLC RG105 CLL RG6268 ROS1+ NSCLC Filed Dec. 2018 Filed Jan 2019 Filed Apr 2019 Filed Mar 2019 Rozlytrek (entrectinib) MabThera Alecensa RG6268 NTRK+ tumor-agnostic RG105 FL RG7853 r/r ALK+ ALCL Filed Jan 2019 Filed Apr 2019 Filed Jun 2019 Kadcyla Avastin HER2+EBC RG405 1L/2L gliobastoma RG3502 Filed Feb 2019 Filed Jan 2019 Venclexta+Gazyva Avastin + Tarceva RG7601 1L CLL RG405 NSCLC Filed Jul 2019 Filed Aug 2019 satralizumab Kadcyla RG6168 NMOSD RG3502 HER2+ eBC Filed Aug 2019 Filed Feb 2019 Perjeta + Herceptin RG6264 1L HER2+ mBC Filed Dec 2018 Perjeta New Molecular Entity (NME) CardioMetabolism RG6264 HER2+ eBC neoadj Additional Indication (AI) Neuroscience Filed Aug 2018 Oncology / Hematology Ophthalmology Gazyva RG7159 1L FL Immunology Other Filed Sep 2019 Infectious Diseases Gazyva RG7159 r/r FL Filed Sep 2019

59 Status as of October 16, 2019 Major granted approvals 2019

US EU China Japan-Chugai

MabThera Herceptin Rituxan Herceptin SC Hylecta RG597 RG105 pemphigus vulgaris RG1569 BC neoadj RG105 CD20+ CLL Feb 2019 Mar 2019 Jan 2019 Mar 2019 Rozlytrek (entrectinib) Hemlibra Perjeta Actemra RG6268 ROS1+ NSCLC RG6013 hemophilia A FVIII non-inh RG6264 HER2+ eBC neoadj RG1569 CRS Aug 2019 Mar 2019 Filed Aug 2018 Mar 2019 Rozlytrek (entrectinib) Hemlibra Actemra RG6268 NTRK+ tumor-agnostic RG6013 Q4W hemophilia A RG1569 Adult Onset Still’s disease Aug 2019 Mar 2019 May 2019 Tecentriq + nab-paclitaxel Tecentriq + chemo + Avastin Rozlytrek RG7446 1L TNBC RG7446 1L non-sq NSCLC RG6268 NTRK+ tumor-agnostic Mar 2019 Mar 2019 June 2019 Tecentriq + chemo Tecentriq + nab-paclitaxel Tecentriq + chemo RG7446 1L extensive stage SCLC RG7446 1L non sq NSCLC RG7446 1L extensive stage SCLC Mar 2019 Sept 2019 Aug 2019 Venclexta + Gazyva Tecentriq + nab-paclitaxel Tecentriq + nab-paclitaxel RG7601 1L CLL RG7446 1L TNBC RG7446 1L TNBC May 2019 Aug 2019 Sept 2019 Kadcyla Tecentriq + chemo RG3502 HER2+ eBC RG7446 1L extensive stage SCLC May 2019 Sept 2019 Polivy (polatuzumab vedotin) New Molecular Entity (NME) CardioMetabolism RG7596 r/r DLBCL Additional Indication (AI) Neuroscience June 2019 Oncology / Hematology Ophthalmology Rituxan Immunology Other RG105 GPA/MPA (pediatrics) Sep 2019 Infectious Diseases

60 Status as of July 25, 2019 Doing now what patients need next